Today: 7 February 2026
Subscribe
Browse Category

NYSE:HRL News 4 December 2025

Hormel Foods (HRL) Stock Rises After Q4 2025 Earnings Miss but Strong 2026 Guidance

Hormel Foods (HRL) Stock Rises After Q4 2025 Earnings Miss but Strong 2026 Guidance

December 4, 2025 Hormel Foods Corporation (NYSE: HRL) is back in the spotlight after reporting fourth-quarter and full‑year fiscal 2025 results and issuing an upbeat earnings outlook for 2026. The branded food company behind SPAM, Skippy, Planters and Jennie‑O posted a rare GAAP loss for the quarter, but investors are focusing on improving margins, stronger guidance and the company’s 60th consecutive annual dividend increase. Hormel Foods+1 How Hormel Foods Stock Is Trading Today Hormel shares were modestly higher in Thursday trading, hovering around the low‑$23 range after earnings, with an intraday range roughly between $23 and $23.50 according to the
4 December 2025
··

Stock Market Today

IBM stock price jumps 3% into weekend as Confluent vote and dividend date near

IBM stock price jumps 3% into weekend as Confluent vote and dividend date near

7 February 2026
New York, February 7, 2026, 15:20 EST — Market closed. International Business Machines Corp shares closed up 3.12% on Friday at $298.93, giving the stock a firmer finish ahead of Monday’s reopen after a choppy week in U.S. tech. The bounce mattered because it landed on a broad risk-on day that pushed the Dow to a first close above 50,000, after three sessions of losses fueled by anxiety over whether big AI budgets will pay off. “There’s enough evidence that there’s real demand for AI products,” Baird investment strategy analyst Ross Mayfield said. (Reuters) Macro data also helped set the
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop